TLSA
NASDAQTiziana Life Sciences Ltd.
News · 26 weeks38+50%
2026-03-012026-08-23
Mix2290d
- SEC Filings8(36%)
- Other7(32%)
- Insider7(32%)
Latest news
25 items- SECSEC Form 6-K filed by Tiziana Life Sciences Ltd.6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
- PRTiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a poster, titled "Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial," will be presented by Dr. Pinar Uysal today, Monday, August 24, 2026, from 4:30–6:30 p.m. ET during the Scientific Poster Session in the Nexus Pavilion at the Hyatt Regency Grand Cypress Resort in Orlando, Florida. Dr. Uysal’s presentation will provide an overview of the BANYAN Trial wit
- INSIDERAmendment: Director Cerrone Gabriele M bought $41,933 worth of shares (42,357 units at $0.99) (SEC Form 4)4/A - Tiziana Life Sciences Ltd (0001723069) (Issuer)
- INSIDERAmendment: Director Cerrone Gabriele M bought $16,650 worth of shares (15,000 units at $1.11) (SEC Form 4)4/A - Tiziana Life Sciences Ltd (0001723069) (Issuer)
- INSIDERChief Executive Officer Elrifi Ivor bought $318,909 worth of shares (321,423 units at $0.99) (SEC Form 4)4 - Tiziana Life Sciences Ltd (0001723069) (Issuer)
- SECSEC Form 6-K filed by Tiziana Life Sciences Ltd.6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
- INSIDERChief Executive Officer Elrifi Ivor bought $667,000 worth of shares (667,000 units at $1.00) (SEC Form 4)4 - Tiziana Life Sciences Ltd (0001723069) (Issuer)
- SECSEC Form 6-K filed by Tiziana Life Sciences Ltd.6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
- PRTiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerBOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Chief Executive Officer, Ivor Elrifi has increased his holdings with the purchase of 667,000 of the Company’s common shares on NASDAQ at $1.00 per share, bringing his total holding to 4,472,261 common shares. About Foralumab Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed int
- SECSEC Form 6-K filed by Tiziana Life Sciences Ltd.6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
- PRTiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal ForalumabBOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative PET imaging results from the third patient with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing. Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to be affected in MSA following treatment with intranasal foralumab. The third MSA patient to complete dosing has shown up to 34% reduction in standardized uptake va
- INSIDERNew insider Elrifi Ivor claimed ownership of 3,805,261 shares (SEC Form 3)3 - Tiziana Life Sciences Ltd (0001723069) (Issuer)
- INSIDERDirector Cerrone Gabriele M was granted 42,357 shares (SEC Form 4)4 - Tiziana Life Sciences Ltd (0001723069) (Issuer)
- SECSEC Form 6-K filed by Tiziana Life Sciences Ltd.6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
- PRTiziana Life Sciences Announces Purchase of Shares by Executive ChairmanBOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 42,357 common shares at $0.99 per share, bringing his total holding to 44,814,587 common shares, which is 34.93% of issued share capital. About Foralumab Foralumab, a fully human anti-CD3 monoclon
- SECSEC Form 6-K filed by Tiziana Life Sciences Ltd.6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
- PRTiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS TrialTop line data readout expected in late Q3/early Q4INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that the last patient in its ongoing Phase 2a clinical trial has received their first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3/early
- INSIDERDirector Cerrone Gabriele M was granted 15,000 shares (SEC Form 4)4 - Tiziana Life Sciences Ltd (0001723069) (Issuer)
- SECSEC Form 6-K filed by Tiziana Life Sciences Ltd.6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
- PRTiziana Life Sciences Announces Purchase of Shares by Executive ChairmanBOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 15,000 common shares at $1.11 per share, bringing his total holding to 44,772,230 common shares, which is 34.89% of issued share capital. About Foralumab Foralumab, a fully human anti-CD3 monoclon
- SECSEC Form 6-K filed by Tiziana Life Sciences Ltd.6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
- PRTiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New YorkBOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that it will present at the Jefferies Global Healthcare Conference taking place in New York City. Ivor Elrifi, Chief Executive Officer and Keeren Shah, Chief Operating and Financial Officer of Tiziana Life Sciences, will deliver a corporate presentation highlighting the Company's recent clinical and corporate updates. Presentation Details:Event: Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Time: 10:30 – 11:00 AM ETLocation: New York, NY The p
- INSIDERNew insider Shah Keeren Rameshchandra claimed ownership of 2,500 shares (SEC Form 3)3 - Tiziana Life Sciences Ltd (0001723069) (Issuer)
- SECSEC Form 6-K filed by Tiziana Life Sciences Ltd.6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
- PRTiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis TrialBOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 of 2026, and will also to be presented at the 10th joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto, Canada in October 2026. The trial
TLSA FAQ
6 questionsWhat does Tiziana Life Sciences Ltd. do?
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule...Where does TLSA stock trade?
Tiziana Life Sciences Ltd. (TLSA) is listed on NASDAQ.What sector and industry is TLSA in?
Tiziana Life Sciences Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Tiziana Life Sciences Ltd. go public?
Tiziana Life Sciences Ltd. (TLSA) completed its IPO in 2018.What companies are similar to TLSA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TLSA side-by-side with any of them on Quantisnow.How can I track TLSA on Quantisnow?
Quantisnow aggregates Tiziana Life Sciences Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TLSA to receive live email and push alerts on every new disclosure.